X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Results at 25 weeks exhibit bystander suppression by delivering only two antigens, indicating the mouse surrogate of RTX-T1D prevented or delayed disease caused by many autoantigens.
Lead Product(s): RTX-T1D
Therapeutic Area: Endocrinology Product Name: RTX-T1D
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
RTX-224 is an allogeneic, off-the-shelf cellular therapy product candidate that is engineered to express hundreds of thousands of copies of 4-1BB ligand (4-1BBL) and interleukin-12 (IL-12) on the cell surface.
Lead Product(s): RTX-224
Therapeutic Area: Oncology Product Name: RTX-224
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Initial results from, RTX-240, an allogeneic, off-the-shelf cellular therapy, Phase 1/2 clinical trial established clinical proof of concept of RTX-240 in advanced solid tumors and clinical validation of RED PLATFORM®.
Lead Product(s): RTX-240
Therapeutic Area: Oncology Product Name: RTX-240
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
RTX-T1D at 25 weeks exhibit bystander suppression by delivering only two antigens, indicating the mouse surrogate of prevented or delayed disease caused by many autoantigens.
Lead Product(s): RTX-T1D
Therapeutic Area: Endocrinology Product Name: RTX-T1D
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2021
Details:
RTX-240 stimulated innate and adaptive immunity as demonstrated by the activation and/or expansion of NK or memory CD8+ T cells in all patients, with 9/16 patients showing activation and expansion in both cell types.
Lead Product(s): RTX-240
Therapeutic Area: Oncology Product Name: RTX-240
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
Initial clinical data show RTX-240 stimulates innate and adaptive immunity (NK Cells and T Cells) supporting proof of mechanism – additional results to be presented in early 2021.
Lead Product(s): RTX-240
Therapeutic Area: Oncology Product Name: RTX-240
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
RTX-240 led to increased CD8 T cell and NK cell expansion and activation in vitro compared to the combination of a 4-1BB agonist antibody plus recombinant IL-15 which was directly correlated with the percentage of 4-1BBL and IL-15TP expressed on the cell surface.
Lead Product(s): RTX-240
Therapeutic Area: Oncology Product Name: RTX-240
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The ongoing study of RTX-240 has two Phase 1 arms, one in all solid tumors and the other in relapsed/refractory AML. RTX-240 is designed to stimulate innate and adaptive immunity by activating NK cells and T cells to generate a potent anti-tumor immune response.
Lead Product(s): RTX-240
Therapeutic Area: Oncology Product Name: RTX-240
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Preclinical data demonstrate that RTX-321 has a dual mechanism of action by not only functioning as an antigen-presenting cell to boost HPV 16 antigen-specific T cell responses, but also promoting broad immune system stimulation of both innate and adaptive immunity.
Lead Product(s): RTX-321
Therapeutic Area: Oncology Product Name: RTX-321
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic™ that is engineered to mimic the human immune system by stimulating adaptive and innate immunity to generate an anti-tumor immune response.
Lead Product(s): RTX-240
Therapeutic Area: Oncology Product Name: RTX-240
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
